Presented at the ACC, the one-year results from the APPOSITION III study, which is assessing the long-term performance of the Stentys Self-Apposing stent in 1,000 with acute myocardial infarction, showed that the Self-Apposing stent (Stentys) is associated with very low rates of mortality 2% and target vessel re-infarction (1.3%).
The APPOSITION III trial is a prospective, single-arm, multicentre study designed to assess the long-term performance of the Self-Apposing Stents in routine clinical practice in Europe among patients suffering from ST-elevation myocardial infarction (STEMI). The primary endpoint, major adverse cardiac events rate at one year was 9.3%. According to a press release, conventional stents averaged 11.1% in a pooled analysis from ACTION Study Group (Pitié-Salpêtrière Hospital, Paris). At the one-year time point, the cardiac death rate was 2.0%, as compared with rates for conventional stents in other published trials which average 3.9%, the lowest rate being 2.2%.
“The very low rates of mortality (2.0%) and target-vessel re-infarction (1.3%) in the APPOSITION III study clearly highlight the excellent safety profile of Self-Apposing stents,” commented Prof. Gilles Montalescot, head of the Cardiac Care Unit at Pitié-Salpêtrière Hospital and investigator of the study, who presents the data at the conference.
When selecting a conventional stent size, there is a risk of under sizing, causing malapposition, or oversizing, causing vessel wall injury; either leads to increased risk of heart attack recurrence. The press release reported that the Stentys Self-Apposing stent solves that “stent-sizing dilemma”: it fits into the contour of a blood vessel, and its shape and diameter adapt as the vessel dilates and the initial clot dissolves during the post-acute myocardial infarction phase.